References

AAMC (Association of American Medical Colleges). 2002. Loan Repayment and Forgiveness Fact Sheet. [Online]. Available: www.aamc.org/students/financing/repayment/nih.htm [accessed May 7, 2002].

AAP (American Academy of Pediatrics). 2000. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases. Pediatrics 106(6):1500–1504.

Acambis, Inc. 2000. Award of Major Contract for Smallpox Vaccine from US CDC. [Online]. Available: www.acambis.com/cfm/index.cfm?cvar=3news2&news_id=509196687 [accessed October 15, 2001].

Acambis, Inc. 2001. Acambis Awarded Two US Grants for Vaccine Programmes. [Online]. Available: www.acambis.com/cfm/index.cfm?cvar=3news2&news_id=21729593 [accessed October 15, 2001].

AEI (American Enterprise Institute for Public Policy Research). 1997. AEI Book Summary. The Search for New Vaccines: The Effects of the Vaccines for Children Program. [Online] Available: http://www.aei.org/bs/bs8117.htm [accessed May 24, 2002].

AFEB (Armed Forces Epidemiological Board). 1991. Coordination of Infectious Disease Research in the Department of Defense. Washington, DC: Armed Forces Epidemiological Board. [Online]. Available: http://www.ha.osd.mil/afeb/1991/1991-04.pdf [accessed June 12, 2002].

AFEB. 1993. Tick-borne Encephalitis Vaccine. [Online]. Available: http://www.ha.osd.mil/afeb/1993/1993-08.pdf [accessed June 7, 2002].

AFEB. 1999. Vaccines in the Military: A Department of Defense-Wide Review of Vaccine Policy and Practice. A report of the Infectious Diseases Control Subcommittee of the Armed Forces Epidemiological Board. Falls Church, VA: Armed Forces Epidemiological Board.

AFEB. 2001. History of the Armed Forces Epidemiological Board. [Online]. Available: http://www.ha.osd.mil/afeb [accessed January 16, 2001].

Airbus. 2002. Overview. [Online]. Available: http://www.airbus.com/about/overview [accessed May 6, 2002].

Antex Biologics, Inc. 2001. U.S. Army Awards SBIR Grant to Antex to Develop Oral Microbead Vaccines Against Diarrhea. [Online]. Available: http://www.antexbiologics/news_pr/pr010116.phtm [accessed March 5, 2002].



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military References AAMC (Association of American Medical Colleges). 2002. Loan Repayment and Forgiveness Fact Sheet. [Online]. Available: www.aamc.org/students/financing/repayment/nih.htm [accessed May 7, 2002]. AAP (American Academy of Pediatrics). 2000. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases. Pediatrics 106(6):1500–1504. Acambis, Inc. 2000. Award of Major Contract for Smallpox Vaccine from US CDC. [Online]. Available: www.acambis.com/cfm/index.cfm?cvar=3news2&news_id=509196687 [accessed October 15, 2001]. Acambis, Inc. 2001. Acambis Awarded Two US Grants for Vaccine Programmes. [Online]. Available: www.acambis.com/cfm/index.cfm?cvar=3news2&news_id=21729593 [accessed October 15, 2001]. AEI (American Enterprise Institute for Public Policy Research). 1997. AEI Book Summary. The Search for New Vaccines: The Effects of the Vaccines for Children Program. [Online] Available: http://www.aei.org/bs/bs8117.htm [accessed May 24, 2002]. AFEB (Armed Forces Epidemiological Board). 1991. Coordination of Infectious Disease Research in the Department of Defense. Washington, DC: Armed Forces Epidemiological Board. [Online]. Available: http://www.ha.osd.mil/afeb/1991/1991-04.pdf [accessed June 12, 2002]. AFEB. 1993. Tick-borne Encephalitis Vaccine. [Online]. Available: http://www.ha.osd.mil/afeb/1993/1993-08.pdf [accessed June 7, 2002]. AFEB. 1999. Vaccines in the Military: A Department of Defense-Wide Review of Vaccine Policy and Practice. A report of the Infectious Diseases Control Subcommittee of the Armed Forces Epidemiological Board. Falls Church, VA: Armed Forces Epidemiological Board. AFEB. 2001. History of the Armed Forces Epidemiological Board. [Online]. Available: http://www.ha.osd.mil/afeb [accessed January 16, 2001]. Airbus. 2002. Overview. [Online]. Available: http://www.airbus.com/about/overview [accessed May 6, 2002]. Antex Biologics, Inc. 2001. U.S. Army Awards SBIR Grant to Antex to Develop Oral Microbead Vaccines Against Diarrhea. [Online]. Available: http://www.antexbiologics/news_pr/pr010116.phtm [accessed March 5, 2002].

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military Associated Press. 2002, February 27. Lyme disease vaccine is taken off of the market. The Washington Post. p. A10. ASA(ALT) (Assistant Secretary of the Army, Acquisition, Logistics, and Technology). 2001. Army Science and Technology Master Plan. [Online]. Available: http://saalt.army.mil/sard-zt/ASTMP01/fm.htm [accessed February 11, 2002]. ASD(HA) (Assistant Secretary of Defense, Health Affairs). 1996. Policy for Tick-borne Encephalitis (TBE) Preventive Measures for US Forces Deployed to Endemic Areas. [Online]. Available: http://www.ha.osd.mil/policies/1996/tbeoje31.html [accessed March 4, 2002]. Bayne-Jones S. 1968. The Evolution of Preventive Medicine in the United States Army, 1607–1939. Washington, DC: Office of the Surgeon General, Department of the Army. BioPort Corporation. 2002. BioPort Corporation Gains FDA Approval. [Online]. Available: http://www.bioport.com/NewsRoom/NewsReleases/BioPort/2002-Jan31.pdf [accessed June 6, 2002]. Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WHH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KPWJ, Tornieporth N, Cohen JD, Doherty T for the RTS,S Malaria Vaccine Trial Team. 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358:1927–1934. Booz Allen and Hamilton. 1999. DoD Cooperative R&D Agreements: Value Added to the Mission. [Online]. Available: http://www.dtic.mil/techtransit/refroom/crada/crada.pdf [accessed May 26, 2002]. Boudreau E, Kortepeter M. 2002. Memorandum from Ellen Boudreau, M.D., Chief, Special Immunizations Program, USAMRIID, and Mark Kortepeter, M.D., Chief, Medical Division, USAMRIID, in response to questions from the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military. March 27. Unpublished data. Brownlee S. 2001, October 28. Clear and present danger. The Washington Post. p. W8. Brundage JF, Zollinger WD. 1987. Evolution of meningococcal disease epidemiology in the U.S. Army. In: Vedros NA, ed. Evolution of Meningococcal Disease. Vol 1. Boca Raton: CRC Press. Pp. 6–25. CDC (Centers for Disease Control and Prevention). 2000a. Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. Morbidity and Mortality Weekly Report: Recommendations and Reports 49(RR-4):1–14. CDC. 2000b. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports 49(RR-7):13–20. CDC. 2001. Two fatal cases of adenovirus-related illness in previously healthy young adults-Illinois, 2000. Morbidity and Mortality Weekly Report 50(26):553–555. CDC. 2002. National Immunization Program: Current Vaccine Shortages. [Online]. Available: http://www.cdc.gov/nip/news/shortages/default.htm [accessed April 25, 2002]. Clayson ET, Vaughn DW, Innis BL, Shrestha MP, Pandey R, Malla DB. 1998. Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal. Journal of Medical Virology 54(3):178–182. Clinton WJ. 1999. Executive Order 13139. Improving health protection of military personnel participating in particular military operations. Federal Register 64(192):54175–54178. Curtin PD. 1989. Death by Migration: Europe’s Encounter with the Tropical World in the Nineteenth Century. Cambridge, U.K.: Cambridge University Press. DA (Department of the Army). 1999. Research, Development, and Acquisition—Army Acquisition Procedures. DA Pamphlet 70-3. Washington, DC: Department of the Army.

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military DHHS (U.S. Department of Health & Human Services). 2001. HHS Awards $428 Million Contract to Produce Smallpox Vaccine: Acambis/Baxter Will Produce 155 Million Doses by the End of 2002. [Online]. Available: http://www.hhs.gov.news/press/2001pres/2001pres/20011128.html [accessed March 4, 2002]. DMM (Directorate of Medical Material). 2002. DAPA (Distribution and Pricing Agreements) Terms and Conditions. [Online]. Available: http://www.dmmonline.com/dmmonline/dapa/dapaterms.asp [accessed April 4, 2002]. DoD (Department of Defense). Office of the Secretary of Defense. 1994. Acquisition Reform: Mandate for Change. [Online]. Available: http://web1.deskbook.osd.mil [accessed November 24, 2001] DoD. 1996. Annual Report to Congress: Nuclear/Biological/Chemical (NBC) Warfare Defense. Washington, DC: Department of Defense. Pp. 1–6. DoD. 2000. Department of Defense Directive: Use of Investigational New Drugs for Force Health Protection (Number 6200.3). Washington, DC: Department of Defense. [Online]. Available: http://www.dtic.mil/whs/directives/corres/dir2.html [accessed March 07, 2002]. DoD. 2001a. Chemical and Biological Defense Program: Research Efforts. [Online]. Available: http://medchembio.detrick.army.mil/MedBio/MedBioResearch.html [accessed March 7, 2001]. DoD. 2001b. Contracts—Army, September 26, 2001. [Online]. Available: www.defenselink.mil/news/sep2001/c09262001_ct461-01.html [accessed October 15, 2001]. DoD. 2001c. Quadrennial Defense Review Report. Washington, DC: Department of Defense. [Online] Available: http://www.defenselink.mil/pubs/qdr2001.pdf [accessed October 2, 2001]. DoD. 2001d. Report on Biological Warfare Defense Vaccine Research and Development Programs. Washington, DC: Department of Defense. [Online]. Available: http://www.defenselink.mil/pubs/ReportonBiologicalWarfareDefenseVaccineRDPrgras-July2001.pdf [accessed September 7, 2001]. DoD. 2001e. Requirements Generation System (CJCSI 3170.01B). Washington, DC: Department of Defense. [Online]. Available: http://web2.deskbook.osd.mil/default.asp? [accessed November 15, 2001]. DoD. 2002. Department of Defense Instruction 5000.2, Including Change 2: Operation of the Acquisition System. Washington, DC: Department of Defense. [Online]. Available: http://www.dtic.mil/whs/directives/ [accessed February 05, 2002]. DSCP (Defense Supply Center Philadelphia). 2002. Defense Supply Center Philadelphia. [Online]. Available: http://dscp305.dscp.dla.mil/dmmonline/pharm/vaccines.asp [accessed January 25, 2002]. DTIC (Defense Technical Information Center). 2002. DOD Dictionary of Military and Associated Terms. [Online] Available: http://www.dtic.mil/doctrine/jel/doddict/ [accessed May 22, 2002]. Edmondson WP, Purcell RH, Gundelfinger BF, Love JWP, Ludwig W, Chanock RM. 1966. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. Specific protective effect against epidemic disease. Journal of the American Medical Association 195(6):453–459. Ellenbogen C. 1982. Infectious diseases of war. Military Medicine 147(3):185–188. Engelman RC, Joy RJT. 1975. Two Hundred Years of Military Medicine. Fort Detrick, MD: U.S. Army Medical Department. FDA (Food and Drug Administration). 1997a. FDA warns Michigan Biologic Products Institute of intention to revoke licenses. [Online]. Available: www.fda.gov/cber/infosheets/mich-inf.htm. [accessed November 1, 2001]. FDA. 1997b. Letter to Edward E. Martin, Acting Assistant Secretary of Defense for Health Affairs from Michael Friedman July 22, 1997. [Online]. Available: http://www.gulflink.osd.mil/library/senate/appx_ee.pdf [accessed April 10, 2002]. FDA. 1997c. Letter to Greer Laboratories. [Online]. Available: http://www.fda.gov/foi/warning_letters/m447n.pdf [accessed February 22, 2002].

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military FDA. 1998. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Washington, DC: Food and Drug Administration. [Online]. Available: http://www.fda.gov/cber/gdlns/clineff.pdf [accessed February 22, 2002]. FDA. 1999. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. 21 CFR § 50 and 312. Federal Register 64(192):54179–54189. FDA. 2001b. Licensed Establishments and Products: July 17, 2001. Center for Biologics Evaluation and Research. [Online]. Available: www.fda.gov/cber/ep/part3.htm [accessed September 26, 2001]. FDA. 2001c. Vaccine Product Approval Process. [Online]. Available: www.fda.gov/cber/vaccine/vacappr.htm [accessed October 22, 2001]. FDA. 2002a. Licensed Establishments and Products: January 10, 2002. Center for Biologics Evaluation and Research. [Online]. Available: www.fda.gov/cber/ep/part3.htm [accessed February 25, 2002]. FDA. 2002b. Molecular Approaches to Enhance Safety of RNA Virus Vaccines. [Online]. Available: http://www.fda.gov/cber/research/0700209.htm [accessed March 15, 2002]. FDA. 2002c. New drug and biological products; evidence needed to demonstrate efficacy of new drugs for use against lethal or permanently disabling toxic substances when efficacy studies in humans ethically cannot be conducted. Final rule. 21 CFR § 314 and 601. Federal Register 67(105):37988–37998. FDA. 2002d. Office of Orphan Product Development. Brief History of the Office. [Online]. Available: www.fda.gov/orphan/history.htm [accessed February 13, 2002]. FMVCC (Federal Malaria Vaccine Coordinating Committee). 2001. U.S. Federal Malaria Vaccine Programs: FMVCC’s Role. [Online]. Available: http://www.fmvcc.gov/role.html [December 7, 2001]. French GR, Plotkin SA. 1999. Miscellaneous limited-use vaccines. In Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: W. B. Saunders Company. Pp. 728–742. GAO (General Accounting Office). 1997. Defense Healthcare: Medical Surveillance Improved Since Gulf War, but Mixed Results in Bosnia. Report GAO/NSAID-97-136. Washington, DC: General Accounting Office. GAO. 2002. Statement of Jack L. Brock, Managing Director, Acquisition, and Sourcing Management and Randolph C. Hite, Director, Information Technology Architecture and Systems. Defense Acquisitions: DoD Faces Challenges in Implementing Best Practices. Report GAO-02-469T. February 27, 2002 hearing of the Subcommittee on Readiness and Management Support, Committee on Armed Services, U.S. Senate, Washington, DC. Gay T. 2002. UK College of Medicine Selected as Site for Smallpox Vaccine Trial. [Online]. Available: http://www.uky.edu/PR/News/smallpoxvac.htm [accessed May 2, 2002]. GBN (Global Business Network). 2002. Scenarios. [Online]. Available: http://www.gbn.org/public/gbnstory/scenarios [accessed June 3, 2002]. Genelabs Technologies. 2001. Genelabs Technologies Announces Phase II Trial for Hepatitis E Virus Vaccine. [Online]. Available: http://www.biospace.com/news_story.cfm?StoryID=6344815&full=1 [accessed March 5, 2002]. Gillert DJ. 1998. DoD: Encephalitis Vaccine Didn’t Threaten Soldier’s Safety. [Online]. Available: http://www.defenselink.mil/news/Feb1998/n02051998_9802054.html [accessed October 30, 2001]. Glenn J. 2000. Research and Development, U.S. Army Medical Research and Materiel Command. Presented at the Third Meeting of the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military, Washington, DC.

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military Goldenthal K. 2000. DoD Limited Use Vaccine Development: Challenges and Approaches. Presented at the Second Meeting of the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military, Washington, DC. Gordon JE. 1958. General Consideration of Modes of Transmission. Medical Department USA. In: Boyd Coates J Jr, ed. Preventive Medicine in World War II: Communicable Diseases Transmitted Chiefly Through Respiratory and Alimentary Tracts. Vol. IV. Washington, DC: Office of the Surgeon General, Department of the Army. Gordon L. 2001. A vaccine manufactured not to be used: contracting for a smallpox vaccine stockpile. In: Ross V, ed. Social Venture Capital for Neglected Vaccine: Creating Successful Alliances: Proceedings of the Albert B. Sabin Vaccine Institute Seventh Annual Vaccine Colloquium at Cold Spring Harbor, New York. New Canaan, CT: The Albert Sabin Institute. Pp. 89– 91. Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC. 1999. Respiratory diseases among U.S. military personnel: countering emerging threats. Emerging Infectious Diseases 5(3):379– 387. Gray GC, Goswami PR, Malasig MD, Hawksworth AW, Trump DH, Ryan MA, Schnurr DP for the Adenovirus Surveillance Group. 2000. Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group. Clinical Infectious Diseases 31(3):663–670. Greco M. 2001. Push and Pull Strategies. First Meeting of the GAVI Partners, November 20–21, Noordwijk. [Online]. Available: http://www.vaccinealliance.org/reference/ppt/greco.ppt [accessed February 20, 2002]. Greer Laboratories. 2001. Letter regarding availability of the plague vaccine. October 11. GSK (GlaxoSmithKline). 2001. Pediatric Clinical Trial for GlaxoSmithKline Malaria Vaccine to Begin Next Month in The Gambia. [Online]. Available: www.worldwidevaccines.com/public/bio/pressr.asp [accessed October 5, 2001]. Hoke CH Jr. 2000a. Military Infectious Diseases Research Program Background. Presented at the First Meeting of the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military , Washington, DC. Hoke CH Jr. 2000b. Requirements revisited. Presented at the Fourth Meeting of the Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military, Washington, DC. Hoke CH Jr. (Director, Military Infectious Disease Research Program, USAMRMC). 2002. Response to request for information from Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military. January 9. Unpublished data. Innis B. 2001. GSK’s Commitment to Vaccine Research: Taking Fear From the Future. [Online]. Available: http://www.worldwidevaccines.com/public/bio/Dominican/Bruce_Innis.ppt [accessed March 5, 2002]. Innis BL, Eckels KH, Kraiselburd E, Dubois DR, Meadors GF, Gubler DJ, Burke DS, Bancroft WH. 1988. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. The Journal of Infectious Diseases 158(4):876–880. IOM (Institute of Medicine). 1985. New Vaccine Development: Establishing Priorities, Vol. I Diseases of Importance in the United States. Washington, DC: National Academy Press. IOM. 1986. New Vaccine Development: Establishing Priorities, Vol. II Diseases of Importance in Developing Countries. Washington, DC: National Academy Press. IOM. 1992. Emerging Infections: Microbial Threats to Health in the United States: Summary. Washington, DC: National Academy Press.

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military IOM. 1993. The Children’s Vaccine Initiative: Achieving the Vision. Washington, DC: National Academy Press. IOM. 2000a. Urgent Attention Needed to Restore Lapsed Adenovirus Vaccine Availability: Letter Report. Washington, DC: National Academy Press. IOM. 2000b. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Academy Press. IOM. 2001. Statement of the Council of the Institute of Medicine. [Online]. Available: http://www.iom.edu/IOM/IOMHome.nsf/Pages/Vaccine+Development [accessed November 5, 2001]. IOM. 2002. The Anthrax Vaccine: Is it Safe, Does it Work? Washington, DC: National Academy Press. Jódar L, Feavers IM, Salisbury D, Granoff DM. 2002. Development of vaccines against meningococcal disease. Lancet 359(9316):1499–1508. Johannes L, McGinley L. 2001, October 19. Search for better anthrax vaccine increases. The Wall Street Journal. p. A9. Johnson-Winegar A (Deputy Assistant to the Secretary of Defense for Chemical/Biological Defense). 2000. Department of Defense Anti-Biological Warfare Vaccine Acquisition Program. Statement at the April 14, 2000 hearing of the Subcommittee on Personnel, Armed Services Committee, U.S. Senate, Washington, DC. Johnson-Winegar A (Deputy Assistant to the Secretary of Defense for Chemical/Biological Defense). 2001. Biowarfare Defense Vaccines. Statement at the October 23, 2001 hearing of the Subcommittee on National Security, Veterans Affairs and International Relations, Committee on Government Reform, U.S. House of Representatives, Washington, DC. JSLD (Joint Staff, Logistics Directorate–J-4). Director for Logistics and Director for Medical Readiness. 1999. Force Health Protection. [Online]. Available: http://www.dtic.mil/jcs/j4/divisions/mrd/fmp.htm [accessed May 23, 2002]. JVAP (Joint Vaccine Acquisition Program). 2001. Joint Vaccine Acquisition Program. [Online]. Available: www.jpobd.net/jvap01.htm [accessed February 21, 2001]. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19(23-24):3179–3188. Kassalow JS. 2001. Why Health is Important to U.S. Foreign Policy. [Online]. Available: http://www.cfr.org/public/pubs/Kassalow_Health_Paper.html [accessed October 8, 2001]. Kelley PW. 1999. Emerging infections as a threat to multinational peacekeeping forces. Médicine Tropicale (Mars) 59(2):137–138. Lang J, Wood S. 1999. Development of orphan vaccines: an industry perspective. Emerging Infectious Diseases 5(6):749–756. Lichtenberg FR. 2001. The Effect of New Drugs on Mortality from Rare Diseases and HIV. Working Paper 8677. Cambridge, MA: National Bureau of Economic Research. [Online]. Available: http:www.nber.org/papers/w8677 [accessed May 30, 2002]. Maiztegui JI, McKee KT Jr, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Briggiler AM, Levis SC, Ambrosio AM, Halsey NA, Peters CJ. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. The Journal of Infectious Diseases 177(2):277–283. McNeill KM, Hendrix RM, Lindner JL, Benton FR, Monteith SC, Tuchscherer MA, Gray GC, Gaydos JC. 1999. Large, persistent epidemic of adenovirus type 4-associated acute respiratory disease in U.S. Army trainees. Emerging Infectious Diseases 5(6):798–801. Michael R. 2000. Prioritization of Research: MIDRP 2001. Presented at the Second Meeting of the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military, Washington, DC.

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military Monath T. 2000. Industry Involvement in Federal Vaccine Development and Procurement Efforts. Presented at the Second Meeting of the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military , Washington, DC. MVI (Malaria Vaccine Initiative). 2001. Clinical Trials of Advanced Malaria Vaccine Candidate Expand to Mozambique. [Online]. Available: www.malariavaccine.org [accessed January 10, 2001]. NAMRU-2. Undated. Early Warning Outbreak Recognition System (EWORS)—Collaboration between the Institute of Health Research and Development, Ministry of Health, Indonesia and U.S. Naval Medical Research Unit 2. Pamphlet presented to subcommittee of the Institute of Medicine Committee to Review the Department of Defense Global Emerging Infections Surveillance and Response System, Indonesia, October 2000. NIAID (National Institute of Allergy and Infectious Diseases). 2000. The Jordan Report 2000. Washington, DC: National Institutes of Health. [Online]. Available: http://www.niaid.nih.gov/publications/pdf/jordan.pdf [accessed February 7, 2001]. NIAID. 2002a. NIAID Phase III HIV Vaccine Trial to Determine Correlates of Protection Will Not Proceed. Phase III Trial in Thailand to Determine Efficacy Will Be Supported by NIAID Through a Combined NIAID-DoD Program. Washington, DC: National Institutes of Health. [Online]. Available: http://www.niaid.nih.gov/newsroom/releases/phase3hiv.htm [accessed March 15, 2002]. NIAID. 2002b. The Counter-Bioterrorism Research Agenda of the National Institute of Allergy and Infectious Disease (NIAID) for CDC Category A Agents. Washington, DC: National Institutes of Health. NIC (National Intelligence Council). 2000. The Global Infectious Disease Threat and Its Implications for the US (Report NIE-99-17D). [Online]. Available: http://www.cia.gov/cia/publications/nie/report/nie99-17d.html [accessed June 3, 2002]. NIH (National Institutes of Health). 2002a. National Institutes of Health: Press Release for the FY 2003 President’s Budget. [Online]. Available: http://www.nih.gov/news/budgetfy2003/2003NIHpresbudget.htm [accessed March 15, 2002]. NIH. 2002b. National Institutes of Health, Office of AIDS Research. [Online]. Available: http://www.nih.gov/od/oar/public/pubs/fy2003/fy2003cj.pdf [accessed June 14, 2002]. NSTC (National Science and Technology Council), Executive Office of the President. 1996. Presidential Decision Directive NSTC-7: Emerging Infections. NSTC-7. NVPO (National Vaccine Program Office). 2001. Committees and Working Groups of the NVPO. [Online]. Available: http://www.cdc.gov/nvpo.committee.htm#iag [accessed December 11, 2001]. Ognibene AJ. 1987. Medical and infectious diseases in the theater of operations. Military Medicine 152(1):14–18. Paul JR, Gardner HT. 1960. Viral Hepatitis. Medical Department USA. Preventive Medicine in World War II: Communicable Diseases Transmitted Through Contact or By Unknown Means. Vol. V. Washington, DC: Office of the Surgeon General, Department of the Army. PhRMA (Pharmaceutical Research and Manufacturers of America). 2000. 2000 Survey: New Medicines in Development for Infectious Diseases. Washington, DC: Pharmaceutical Research and Manufacturers of America. Pittman P. 2000. Status of Limited Use Vaccines in the Military. Presented at the Second Meeting of the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military, Washington, DC. Republican Policy Committee. 1986. Senate Record Vote Analysis, 99th Congress: DoD Reorganization. [Online]. Available: www.senate.gov/~rpc/rva/992/99293.htm [accessed May 26, 2002].

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military Rettig RA. 1999. Military Use of Drugs Not Yet Approved by the FDA for CW/BW Defense. RAND Report #MR-1018/9-OSD. Santa Monica, CA: RAND Institute. [Online]. Available: http://www.rand.org/publications/MR/MR1018.9/ [accessed November 17, 2001]. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. 2002. Report summary: public health assessment of potential biological terrorism agents. Emerging Infectious Diseases 8(2):225– 230. Sanchez JL, Binn LN, Innis BL, Reynolds RD, Lee T, Mitchell-Raymundo F, Craig SC, Marquez JP, Shepherd GA, Polyak CS, Conolly J, Kohlhase KF. 2001. Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adults. Journal of Medical Virology 65(4):710–718. Secretaries of the Air Force, Army, Navy, and Transportation. 1995. Air Force Joint Instruction 48-110, Army Regulation 40-562, Bureau of Medicine & Surgery Instruction 6230.15, Coast Guard Commandant Instruction M6230.4E. Immunizations and Chemoprophylaxis. [Online]. Available: http://www.dtic.mil/whs/directives/ [accessed November 15, 2001]. SEMATECH. 2002. Corporate Information: History. [Online]. Available: http://www.sematech.org/public/corporate/index.htm [accessed April 2, 2002]. Scott B. 2000. Requirements Determination. Presented at the Third Meeting of the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military, Washington, DC. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. New England Journal of Medicine 336(2):86–91. Top FH Jr., Grossman RA, Bartelloni PJ, Segal HE, Dudding BA, Russell PK, Buescher EL. 1971. Immunization with live types 7 and 4 adenovirus vaccines: safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. The Journal of Infectious Diseases 124(2):148–154. TRADOC (U.S. Army Training and Doctrine Command). 1986. Operational and Organizational (O&O) Plan for Medical Defense Against Infectious Disease. Fort Monroe, VA: U.S. Army Training and Doctrine Command. TRADOC. 1999. Force Development—Requirements Determination. TRADOC pamphlet 71-9. [Online]. Available: http://www-tradoc.army.mil/tpubs/pams/p71-9/1999/p71-9.html [accessed November 24, 2001]. USAMMDA (U.S. Army Medical Materiel Development Activity). 2001a. USAMMDA Information Paper—TBE. [Online]. Available: http://www.armymedicine.army.mil/usammda/info335.pdf [accessed November 24, 2001]. USAMMDA. 2001b. USAMMDA Information Paper—Shigella. [Online]. Available: http://www.armymedicine.army.mil/usammda/info363.pdf [accessed November 24, 2001]. USAMMDA. 2001c. USAMMDA Information Paper—Campylobacter. [Online]. Available: http://www.armymedicine.army.mil/usammda/info196.pdf [accessed November 24, 2001]. USAMRMC (U.S. Army Medical Research and Materiel Command). 1999. Medical Products for Supporting Military Readiness: Vaccines & Drugs (GO Book). Washington, DC: Department of Defense. USAMRMC. 2001a. USAMRMC: Command Brochure. [Online]. Available: http://mrmc-www.army.mil/ [accessed November 24, 2001]. USAMRMC. 2001b. USAMRMC: Command Organizations. [Online]. Available: http://mrmc.detrick.army.mil/ [accessed November 24, 2001]. USAMRMC. 2001c. USAMRMC: Command Overview. [Online]. Available: http://mrmc.detrick.army.mil/hdqoverview.asp [accessed November 24, 2001]. USAMRMC. 2001d. USAMRMC: Organization Chart. [Online]. Available: http://mrmc.detrick.army.mil/hdqorgchart.asp [accessed November 24, 2001].

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military USAMRMC. 2002a. CSI Research: Research Area Directorates. [Online]. Available: http://mrmc.detrick.army.mil/crprads.asp [accessed February 28, 2002]. USAMRMC. 2002b. USAMRMC: Organization Chart. [Online]. Available: http://mrmc.detrick.army.mil/hdqorgchart.asp [accessed June 13, 2002]. U.S. Military HIV Research Program. 2002. Overview. [Online]. Available: http://www.hivresearch.org/overview/index.html [accessed May 27, 2002]. Vaccine Stockpile Strategy. 2002. Vaccine Stockpile Strategy Cost Implications Should Be Considered—NVAC. “The Pink Sheet”: Prescription Pharmaceuticals and Biotechnology 64(14):31. Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM, Bhamarapravati N. 1996. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14(4):329–336. WHO (World Health Organization). 2002. Dengue Fever. [Online]. Available: http://www.who.int/tdr/diseases/dengue/dengue-poster.pdf [accessed March 5, 2002]. Widdus R. 2001. Public-private partnerships for health: their main targets, their diversity, and their future directions. Bulletin of the World Health Organization 79(8):713–720. Zoon KC. 2000. Statement of Kathryn Zoon, Ph.D., Director of the Center for Biologics Evaluation and Research, Food and Drug Administration, on the anthrax vaccine to the Committee on Armed Services, U.S. Senate, Washington, DC. Zoon KC, Goldman B (Director, Center for Biologics Evaluation and Research, Food and Drug Administration; Special Assistant, Associate Director for Regulatory Policy, Office of Vaccines Regulation and Research, Food and Drug Administration). 2002. Memorandum in response to questions from the Institute of Medicine Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military. February 11. Unpublished data.

OCR for page 95
Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military This page in the original is blank.